Cervical cancer ranks as the fourth most prevalent cancer among women globally, with approximately 600,000 new cases being diagnosed each year. The principal driver of cervical cancer is the human papillomavirus (HPV), where viral oncoproteins E6 and E7 undertake the role of driving its carcinogenic potential. Despite extensive investigative efforts, numerous facets concerning HPV infection, replication, and pathogenesis remain shrouded in uncertainty. The virus operates through a variety of epigenetic mechanisms, and the epigenetic signature of HPV-related tumors is a major bottleneck in our understanding of the disease. Recent investigations have unveiled the capacity of viral oncoproteins to influence epigenetic changes within HPV-related tumors, and conversely, these tumors exert an influence on the surrounding epigenetic landscape. Given the escalating occurrence of HPV-triggered tumors and the deficiency of efficacious treatments, substantial challenges emerge. A promising avenue to address this challenge lies in epigenetic modulators. This review aggregates and dissects potential epigenetic modulators capable of combatting HPV-associated infections and diseases. By delving into these modulators, novel avenues for therapeutic interventions against HPV-linked cancers have come to the fore.
宫颈癌在全球女性常见癌症中位列第四，每年新增确诊病例约60万例。其主要致病因素是人乳头瘤病毒（HPV），该病毒的致癌潜能主要由病毒癌蛋白E6和E7驱动。尽管已开展大量研究，HPV感染、复制及致病机制中的诸多层面仍存在未解之谜。该病毒通过多种表观遗传机制发挥作用，而HPV相关肿瘤的表观遗传特征正是我们理解该疾病的主要瓶颈。最新研究揭示了病毒癌蛋白能够影响HPV相关肿瘤内部的表观遗传变化，反之这些肿瘤也会对周围表观遗传环境产生影响。鉴于HPV诱发肿瘤的发病率持续攀升且缺乏有效治疗手段，我们正面临重大挑战。表观遗传调节剂为此提供了具有前景的解决路径。本综述系统整合并剖析了可能对抗HPV相关感染及疾病的潜在表观遗传调节剂。通过对这些调节剂的深入探究，针对HPV相关癌症的新型治疗路径已逐渐显现。
肿瘤(癌症)患者之家